Monoamine neurotransmitter system (MNS) (MNS)

The serotonin-dopamine-norepinephrine monoamine neurotransmitter system is a complex network of pathways in the central nervous system that regulates a wide array of physiological and cognitive functions (StatPearls, 2023). It comprises neurons that synthesize and release serotonin, dopamine, and norepinephrine, along with their specific transporters (SERT, DAT, and NET) and a diverse set of receptors (NIH, 2022). This system is fundamental to the regulation of mood, reward, motivation, attention, and autonomic functions. Dysregulation within these pathways is linked to various psychiatric and neurological conditions, including depression, ADHD, and Parkinson's disease (PubMed, PMID: 24569768). Pharmacological intervention often involves triple reuptake inhibitors (SNDRIs) or multi-target agents designed to restore balance across all three neurotransmitter levels. However, broad modulation of this system carries risks such as serotonin syndrome and cardiovascular complications due to the widespread influence of these monoamines (PubMed, PMID: 19702553).

Other names

Monoaminergic systemSerotonin-dopamine-norepinephrine systemTri-monoaminergic systemSND system

The system is modulated by drugs that inhibit the reuptake of serotonin, dopamine, and norepinephrine by binding to their respective transporters (SERT, DAT, and NET), thereby increasing the synaptic availability of these neurotransmitters (PubMed, PMID: 19702553). It is also affected by agents that act as agonists or antagonists at various monoamine receptors or inhibit metabolic enzymes like monoamine oxidase (StatPearls, 2023).